- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05009953
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xiangdong Cheng, Ph.D
- Phone Number: 0086-10-010-87788826
- Email: Chenxd516@126.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
-
Contact:
- Xiangdong Cheng
- Email: Chenxd516@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. At least 18 years of age, regardless of gender. 2.Histologically or cytologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of biliary tract, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBC).
3.At least one measurable lesion according to RECIST 1.1. 4.Previous first-line standard system chemotherapy failed. First-line standard chemotherapy is defined as gemcitabine combined with capecitabine or platinum.
5.Patients with prior local treatment (embolization, chemoembolization, radiofrequency ablation, or radical radiotherapy) must be completed at least 4 weeks before the first administration of the study drug, palliative decompensated radiotherapy (such as bone metastases) must be completed at least 2 weeks before the first administration of the study drug.
6.Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. 7.Life expectancy >3 months. 8.Adverse reactions must recover to grade 1 or baseline according to CTCAE 5.0 (except for toxicity such as alopecia, grade 2 or less sensory neuropathy, etc., which have been judged no safety risk by investigators).
9.Patients should not receive cell growth factors or blood and platelet transfusion within 7 days before the initiate administration of study drug, and laboratory test should meet the following criteria: neutrophile count ≥1.5×10^9/L;platelet count ≥90×10^9/L; hemoglobin ≥90 g/L or ≥5.6 mmol/L;serum creatinine ≤1.5×ULN or creatinine clearance rate must be ≥ 50 mL/min when serum creatinine >1.0×ULN;total bilirubin ≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN or ≤2.5×ULN if intrahepatic lesions exist;Albumin ≥3 g/dL.
10. Activated Partial Thromboplastin Time (APTT), International Normalized Ratio (INR) and prothrombin time (PT) ≤1.5 × ULN for patients not receiving therapeutic anticoagulation.
11.Patients with biliary obstruction or no evidence of persistent infection should receive adequate biliary drainage; active or suspected infections are not allowed.
12. Female patients with reproductive potential must agree to use adequate contraception from the signing of informed consent to at least 6 months after the study completion and have a negative serum pregnancy test within 7 days before enrollment, and must be non-lactating. Male patients must agree to use medically approved contraception during the study and for 6 months after the study period.
13. Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
1. Patients with definite positive NTRK fusion gene. 2. Patients who have received any investigational drug within 4 weeks prior to the first dose of irinotecan liposomes injection.
3. Patients with definite metastatic encephalopathy. 4. Patients who have received liver transplantation or liver metastases accounted for 50% or more of the total liver volume.
5. Patients with hepatic encephalopathy. 6. Uncontrolled third lacunar effusion other than ascites (e.g., large pleural or pericardial effusion).
7. Previous malignancies in the past five years (except radically resected and non-recurring basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, local prostate carcinoma, carcinoma in situ of cervical, or other carcinoma in situ).
8. History of serious cardiovascular disease. 9. Patients with uncontrolled active bleeding. 10. Gastrointestinal diseases of clinical significance, such as bleeding, inflammation, obstruction, >grade 1 diarrhea, etc.
11. Patients with definite Gilbert syndrome. 12. Patients who have concomitant use of strong CYP3A4 inducers within 2 weeks prior to the first dose, or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 1 week prior to the first dose.
13. Patients who received systemic glucocorticoids or other immunosuppressive agents within 14 days before the first dose of the study drug.
14. Patients who have undergone major organ surgery within 4 weeks prior to the first dose of the study drug.
15. Patients who are hypersensitivity to any component of irinotecan liposome injection or other liposome products.
16. Patients who are allergic to gemcitabine, cisplatin, fluorouracil or leucovorin or its components.
Additional exclusion criteria for cohort 2:
- Patients who have received any other antibodies or drugs that act on T-cell synergetic stimulation or checkpoint pathways (including PD-1, PD-L1, CTLA-4 inhibitors, etc.).
- Patients with a history of severe allergic reactions to monoclonal antibodies and uncontrolled allergic asthma.
- Patients with active autoimmune disease or a history of autoimmune diseases.
- History of primary immunodeficiency.
- Patients who occurred immune related adverse events.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- Received live attenuated vaccine within 14 days before screening period or planned to received it during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Irinotecan Liposome Injection + 5-FU/LV
The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
|
Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
|
Experimental: Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV
The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
|
Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to six months after the last patient's first administration
|
The percentage of patients who achieve a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
|
Up to six months after the last patient's first administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UGT1A1
Time Frame: Within 3 days before the first dose
|
UGT1A1 gene polymorphism
|
Within 3 days before the first dose
|
Progression-Free Survival (PFS)
Time Frame: Up to six months after the last patient's first administration
|
Time from date of the first dose to date of recorded disease progression or death, whichever occurs first
|
Up to six months after the last patient's first administration
|
Overall survival (OS)
Time Frame: Up to six months after the last patient's first administration
|
Time from date of the first dose to date of death from any cause
|
Up to six months after the last patient's first administration
|
Disease Control Rate (DCR)
Time Frame: Up to six months after the last patient's first administration
|
The percentage of patients who achieve a CR, PR or stable disease (SD) based on the RECIST 1.1
|
Up to six months after the last patient's first administration
|
Duration of Response (DOR)
Time Frame: Up to six months after the last patient's first administration
|
Time from first documented response (CR or PR whichever occurs first, based on investigator's assessment per RECIST 1.1) to date of disease progression or death due to any cause, whichever occurs first
|
Up to six months after the last patient's first administration
|
Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to six months after the last patient's first administration
|
The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0
|
Up to six months after the last patient's first administration
|
Peak Plasma Concentration
Time Frame: 0-240 h of circle 1 to circle 4
|
Cmax
|
0-240 h of circle 1 to circle 4
|
Area under the plasma concentration versus time curve
Time Frame: 0-240 h of circle 1 to circle 4
|
AUC
|
0-240 h of circle 1 to circle 4
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiangdong Cheng, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Biliary Tract Diseases
- Cholangiocarcinoma
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Leucovorin
- Irinotecan
Other Study ID Numbers
- HE072-CSP-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic CholangiocarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnBile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic CholangiocarcinomaUnited States
-
Rutgers, The State University of New JerseyRecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, IntrahepaticUnited States
Clinical Trials on Irinotecan Liposome Injection
-
Fudan UniversityNot yet recruitingSmall Cell Lung Cancer RecurrentChina
-
Luye Pharma Group Ltd.CompletedAdvanced Solid TumorChina
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Breast Cancer
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingSmall Cell Lung Cancer (SCLC)
-
Luye Pharma Group Ltd.RecruitingRelapsed Small Cell Lung CancerChina
-
Yakult Honsha Co., LTDCompleted
-
Luye Pharma Group Ltd.CompletedSmall Cell Lung CancerChina
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine GliomaUnited States
-
Peking University People's HospitalPeking University Shougang Hospital; Shandong Cancer Hospital and InstituteRecruiting